COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder
November 03, 2021 08:00 ET
|
COMPASS Pathways
London, UK – 3 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups
October 20, 2021 09:00 ET
|
COMPASS Pathways
Investigator-initiated study shows remission in major depression symptoms for 50% of participants London, UK – 20 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health...
COMPASS Pathways is granted new US patent for crystalline psilocybin
October 19, 2021 07:00 ET
|
COMPASS Pathways
London, UK – 19 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways to participate in upcoming Maxim and Cantor investor conferences
September 21, 2021 08:00 ET
|
COMPASS Pathfinder Ltd.
London, UK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
September 14, 2021 07:00 ET
|
COMPASS Pathfinder Ltd.
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has acquired an...
Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds
September 10, 2021 07:00 ET
|
COMPASS Pathfinder Ltd.
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has engaged Hamilton Morris,...
COMPASS Pathways to participate in Citi, Morgan Stanley and HC Wainwright investor conferences in September
September 07, 2021 10:00 ET
|
COMPASS Pathfinder Ltd.
London, UK – Sept. 07, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based...
COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021
August 11, 2021 07:00 ET
|
COMPASS Pathfinder Ltd.
Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021 Partnership being developed with leading UK...
COMPASS Pathways plc to announce second quarter 2021 financial results on 11 August 2021
August 04, 2021 08:27 ET
|
COMPASS Pathfinder Ltd.
London, UK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
COMPASS Pathways to Participate in BTIG and Canaccord Genuity Investor Conferences
August 03, 2021 08:00 ET
|
COMPASS Pathfinder Ltd.
London, UK , Aug. 03, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...